Cancer is a major public health problem worldwide with more than an estimated 19.3 million
new cases in 2020. The occurrence rises dramatically with age, and the overall risk …

While human epidermal growth factor receptor 2 (HER2) aberrations have long been
described in patients with non-small cell lung cancer (NSCLC), they have only recently been …

Oncogenic mutations and amplifications in the erythroblastic oncogene B (ERBB2), or
human epidermal growth factor receptor 2 (HER2), have emerged as distinct oncogenic …

Objective Besides breast and gastric cancer, HER2 amplification/mutation are also found in
lung adenocarcinoma (LUAD). However, the correlation between HER2 variations and the …

Background Human epidermal growth factor receptor 2 (HER2), a promising therapeutic
target, can be mutated, amplified, or overexpressed in different malignancies, including non …

Objective We analyze and identify the signals of gender differences in adverse events
(ADEs) related to Osimertinib and provide reference for clinical implementation of …

This work reports the development of a gallium nitride-based high electronic mobility
transistor (GaN HEMT)-based biosensor to detect human epidermal growth factor receptor-2 …

Simple Summary There are growing data on targeting HER2 alterations, which include gene
mutations, gene amplifications, and protein overexpression, for non-small cell lung cancer …

Dual targeting of epidermal growth factor receptor (EGFR) and human EGFR-related
receptor 2 (HER2) is a proven approach for the treatment of lung cancer. With the aim of …

HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are
distinct molecular alterations identified via next generation sequencing (NGS). Previously …